25I-NBMD

25I-NBMD

Systematic (IUPAC) name
2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2,3-methylenedioxyphenyl)methyl]ethanamine
Identifiers
CAS Number	919797-25-4 N
ChemSpider	26234932 Y
UNII	R99110126K Y
Chemical data
Formula	C18H20INO4
Molecular mass	441.259 g/mol
SMILES c13OCOc3cccc1CNCCc(c(OC)cc2I)cc2OC
InChI InChI=1S/C18H20INO4/c1-21-16-9-14(19)17(22-2)8-12(16)6-7-20-10-13-4-3-5-15-18(13)24-11-23-15/h3-5,8-9,20H,6-7,10-11H2,1-2H3 Y Key:NJNMIPDEUMTYNV-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

25I-NBMD (NBMD-2C-I, Cimbi-29) is a derivative of the phenethylamine hallucinogen 2C-I, discovered in 2006 by a team at Purdue University led by David Nichols. It acts as a potent partial agonist for the 5HT_2A receptor with a Ki of 0.049nM at the human 5HT_2A receptor. The corresponding 4-bromo analogue 25B-NBMD has been used for molecular dynamics studies on the shape of the 5-HT_2A receptor. Common doses are reported to be between 500 µg and 1.5 mg. Although the low end of the dose response curve is similar to LSD, being active at 500 µg, some reports show 1.5–2.0 mg being a low dose, making it up to four times less active than its nbome counterpart 25I-NBOMe. As a recreational drug, 25I-NBMD has not been on the open market for long; therefore there are very few reports about its use.

Legality

Sweden's public health agency suggested to classify 25I-NBMD as hazardous substance on November 10, 2014.

See also

• 2CBCB-NBOMe (NBOMe-TCB-2)
• 2CBFly-NBOMe (NBOMe-2CB-Fly)
• 25B-NBOMe (NBOMe-2CB)
• 2C-C-NBOMe (NBOMe-2CC)
• 25B-NBOH
• 25I-NBOH (NBOH-2CI)
• 25I-NBOMe (NBOMe-2CI)
• 25I-NB34MD (NB34MD-2CI)
• 2C-TFM-NBOMe (NBOMe-2C-TFM)
• 25I-NBF (NBF-2CI)